610
Participants
Start Date
November 14, 2022
Primary Completion Date
August 21, 2023
Study Completion Date
April 16, 2024
Placebo
Placebo administered subcutaneously (SC) once a week.
IBI362
IBI362 administered subcutaneously (SC) once a week.
People's Hospital of Peking University, Beijing
Xuancheng People's Hospital, Xuancheng
Luoyang Third People's Hospital, Luoyang
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang
The First Affiliated Hospital of Nanyang Medical University, Nanyang
The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang
Hebei Petro China Central Hospital, Langfang
The First People's Hospital Of Kunshan, Kunshan
Nanjing Drum Tower Hospital, Nanjing
Affiliated Hospital Of Nantong University, Nantong
Suzhou Municipal Hospital, Suzhou
Pingxiang People's Hospital, Pingxiang
China-Japan Union Hospital of Jilin University, Changchun
Shenyang Fifth People's Hospital, Shenyang
Jinan Central Hospital, Ji'nan
Shandong Provincial Third Hospital, Ji'nan
Qilu Hospital Of Shandong University (Qingdao), Qingdao
Tai'an Central Hospital, Tai’an
Zibo Municipal Hospital, Zibo
Shanxi Bethune Hospital, Taiyuan
Yan'an University Xianyang Hospital, Xianyang
Huzhou Central Hospital, Huzhou
Lishui Central Hospital, Lishui
Innovent Biologics (Suzhou) Co. Ltd.
INDUSTRY